GC Biopharma

GC Biopharma ROA

The Return on Assets (ROA) of GC Biopharma (006280.KS) as of Nov 5, 2026 is -0.16 %. In the previous year, Return on Assets (ROA) was -0.96 % — a change of -83.58% (higher).

ROA

-0.16 %

YoY

-83.58%

Last updated:

In 2025, GC Biopharma's return on assets (ROA) was -0.16 %, a -83.58% increase from the -0.96 % ROA in the previous year.

The GC Biopharma ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2018
2.00 KRW
Jan 1, 2019
-0.19 KRW
Jan 1, 2020
3.77 KRW
Jan 1, 2021
5.00 KRW
Jan 1, 2022
2.59 KRW
Jan 1, 2023
-1.01 KRW
Jan 1, 2024
-0.96 KRW
Jan 1, 2025
-0.16 KRW
The GC Biopharma ROA history
YEARROAYoY
-0.16 %-83.58%
-0.96 %-4.94%
-1.01 %-138.88%
2.59 %-48.21%
5.00 %+32.84%
3.77 %-2,129.17%
-0.19 %-109.29%
2.00 %-36.08%
3.13 %-23.03%
4.06 %-39.49%
6.71 %+6.35%
6.31 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

GC Biopharma Stock analysis

What does GC Biopharma do? GC Biopharma Corp generates revenue through the production and sale of pharmaceutical products such as blood products, general products, vaccines, over-the-counter drugs, diagnostic reagents, placental injections, cell therapies, and blood diagnostic products. The company also offers genome analysis services. Its primary customers include healthcare providers and institutions requiring pharmaceuticals and diagnostic solutions. The firm targets segments focused on biopharmaceutical manufacturing and genomic healthcare services. Green Cross Corp, the parent company, operates under the same business model, emphasizing pharmaceutical manufacturing and genomic services. The company's product portfolio spans blood-related treatments, vaccines, and advanced diagnostic tools, catering to both general medical needs and specialized healthcare applications. Revenue streams are derived from direct sales of these products and services to healthcare sectors. The business model integrates the production of traditional pharmaceuticals with innovative genomic services, creating a diversified revenue base. Key segments include blood product manufacturing, vaccine development, and diagnostic reagent sales, alongside cell therapy and placental injection offerings. Customers are primarily healthcare institutions and providers seeking comprehensive pharmaceutical and diagnostic solutions. GC Biopharma is one of the most popular companies on Eulerpool.

ROA Details

Understanding GC Biopharma's Return on Assets (ROA)

GC Biopharma's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing GC Biopharma's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider GC Biopharma's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in GC Biopharma’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about GC Biopharma stock

Return on Assets (ROA) of GC Biopharma is -0.16 % in 2025.

Return on Assets (ROA) of GC Biopharma changed from -0.96 % to -0.16 %, representing a -83.58% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) GC Biopharma since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s GC Biopharma with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — GC Biopharma

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — GC Biopharma